CompletedNCT00089843
Testosterone or risedronate for bone loss in women with anorexia
Medication studyAges 18–45United StatesEating disorders
Understand this study
Who was this study for?
Listed age limits: 18 years to 45 years.
- Listed locations
- BostonSee all locations and recruitment
- Study phase
- Phase 2 / Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
Study information
Study start dateJune 2003
- Recruitment status
- Completed
- Enrollment listed in the registry
- 77
- Sponsor
- Massachusetts General Hospital
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2 / Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
- Locations
- United States
- Age range
- From 18 Years to 45 Years
- Official registry ID
- NCT00089843
- Official title
Show the full official title
IGF-1 and Bone Loss in Women Anorexia Nervosa
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Boston
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Massachusetts General Hospital, a hospital or academic medical center.
Did this study involve medication?
Yes. The study involved medication, including Testosterone, Actonel (risedronate), Placebo Actonel (risedronate) and Placebo testosterone.
Who was this study for?
Listed age limits: 18 years to 45 years.
